<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin. Cancer Res.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC4359951</article-id>
        <article-id pub-id-type="pmcid-ver">PMC4359951.1</article-id>
        <article-id pub-id-type="pmcaid">4359951</article-id>
        <article-id pub-id-type="pmcaiid">4359951</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS656215</article-id>
        <article-id pub-id-type="pmid">25589618</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1773</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS656215</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA656215</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Genomic analysis of metastatic cutaneous squamous cell carcinoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Li</surname>
              <given-names initials="YY">Yvonne Y.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hanna</surname>
              <given-names initials="GJ">Glenn J.</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Laga</surname>
              <given-names initials="AC">Alvaro C.</given-names>
            </name>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Haddad</surname>
              <given-names initials="RI">Robert I.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A5">5</xref>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lorch</surname>
              <given-names initials="JH">Jochen H.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A5">5</xref>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="author-notes" rid="FN1">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hammerman</surname>
              <given-names initials="PS">Peter S.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A5">5</xref>
            <xref ref-type="aff" rid="A6">6</xref>
            <xref ref-type="author-notes" rid="FN1">*</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA</aff>
        <aff id="A2"><label>2</label>Broad Institute, Cambridge, MA</aff>
        <aff id="A3"><label>3</label>Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA</aff>
        <aff id="A4"><label>4</label>Department of Dermatology, Brigham and Women's Hospital, Boston, MA</aff>
        <aff id="A5"><label>5</label>Department of Medicine, Brigham and Women's Hospital, Boston, MA</aff>
        <aff id="A6"><label>6</label>Department of Medicine, Harvard Medical School, Boston, MA</aff>
        <author-notes>
          <corresp id="cor1"><bold>Corresponding authors</bold>. Peter Hammerman, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-6049. Fax: 617-632-5786. <email>Peter_Hammerman@dfci.harvard.edu</email>. Jochen Lorch, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-3090. Fax: 617-632-4448. <email>Jochen_Lorch@dfci.harvard.edu</email></corresp>
          <fn id="FN1" fn-type="equal">
            <label>*</label>
            <p id="P1">These authors contributed equally to this article.</p>
          </fn>
          <fn id="FN2" fn-type="conflict">
            <p id="P49">
              <bold>Disclosure of Potential Conflicts of Interest</bold>
            </p>
            <p id="P50">No potential conflicts of interest were disclosed by the other authors.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>14</day>
          <month>1</month>
          <year>2015</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>15</day>
          <month>3</month>
          <year>2015</year>
        </pub-date>
        <volume>21</volume>
        <issue>6</issue>
        <issue-id pub-id-type="pmc-issue-id">250527</issue-id>
        <fpage>1447</fpage>
        <lpage>1456</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>17</day>
              <month>01</month>
              <year>2015</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>15</day>
              <month>03</month>
              <year>2016</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>15</day>
              <month>03</month>
              <year>2016</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-04-04 15:25:35.543">
              <day>04</day>
              <month>04</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms656215.pdf"/>
        <abstract>
          <sec id="S1">
            <title>Purpose</title>
            <p id="P2">A rare 5% of cutaneous squamous cell carcinomas metastasize, lack FDA-approved therapies, and carry a poor prognosis. Our aim was to identify recurrent genomic alterations in this little-studied population of metastatic cSCCs.</p>
          </sec>
          <sec id="S2">
            <title>Experimental Design</title>
            <p id="P3">We performed targeted sequencing of 504 cancer-associated genes on lymph node metastases in 29 patients with cSCC and identified mutations and somatic copy number alterations associated with metastatic cSCC. We determined significantly mutated, deleted and amplified genes and associated genomic alterations with clinical variables.</p>
          </sec>
          <sec id="S3">
            <title>Results</title>
            <p id="P4">The cSCC genome is heterogeneous with widely varying numbers of genomic alterations and does not appear to be associated with HPV. We found previously identified recurrently altered genes (<italic toggle="yes">TP53, CDKN2A, NOTCH1/2</italic>) but also a wide spectrum of oncogenic mutations affecting RAS/RTK/PI3K, squamous differentiation, cell cycle, and chromatin remodeling pathway genes. Specific mutations in known oncogenic drivers and pathways were correlated with inferior patient outcomes. Our results suggest potential therapeutic targets in metastatic cSCC including <italic toggle="yes">PIK3CA, FGFR3, BRAF,</italic> and <italic toggle="yes">EGFR</italic>, similar to those reported in SCCs of the lung and head and neck, suggesting that clinical trials could be developed to accrue patients with SCCs from multiple sites of origin.</p>
          </sec>
          <sec id="S4">
            <title>Conclusions</title>
            <p id="P5">We have genomically characterized a rare cohort of 29 metastatic cSCCs and identified a diverse array of oncogenic alterations that can guide future studies of this disease.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>squamous cell carcinomas</kwd>
          <kwd>cancer genomics</kwd>
          <kwd>skin cancer</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
